Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
- 1 December 2006
- journal article
- Published by Elsevier BV in Surgery
- Vol. 140 (6), 968-977
- https://doi.org/10.1016/j.surg.2006.07.030
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patientsLiver Transplantation, 2006
- 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal ModelClinical Cancer Research, 2006
- The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasmsSurgery, 2004
- Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine TumorsMolecular Imaging & Biology, 2003
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceSeminars in Nuclear Medicine, 2002
- Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignanciesSeminars in Nuclear Medicine, 2002
- Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary dataEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG)European Journal of Gastroenterology & Hepatology, 1999
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993